Research a compound stack end to end — a structured protocol scaffold, how VialTalk researchers actually combine these compounds, receptor conflicts, and live COA-verified prices. Add 1–5 compounds.
Research signals
Redundancy, true conflicts, and dangerous additive effects
Review advised
No documented conflicts — some notes to review
Receptor activity map
| Receptor | Retatrutide | Tesamorelin | MOTS-c | 5-Amino-1MQ |
|---|---|---|---|---|
| GLP-1 receptor (GLP-1R) | ||||
| GIP receptor (GIPR) | ||||
| Glucagon receptor (GCGR) | ||||
| GHRH receptor | ||||
| AMPK pathway | ||||
| NNMT (nicotinamide N-methyltransferase) |
A structured, research-grounded protocol for this stack
Sign in to build a structured research protocol scaffold for 5-Amino-1MQ + MOTS-c + Retatrutide + Tesamorelin — phases, per-compound parameters, endpoints and washout, grounded in documented research.
What VialTalk researchers actually run
1 researcher has logged this combination on VialTalk
Lose weight sustainably with minimal side effects
by Shawn · 42 reads
Most common doses logged
Researchers are also adding
Early signal — this combination is newly tracked. The picture sharpens as more researchers log it.
Best price for each compound today
Same “From” price shown on each compound's page (after discounts). Panels = COA assays tested. Tap “Compare all vendors” for the full breakdown.
For research and informational use only. VialTalk does not provide medical advice or dosing guidance. Community data reflects self-reported public research journals.